Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis

Infliximab is a promising drug with good outcomes demonstrated for diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthropathy (SpA). However, treatment with this drug may increase the risk of tuberculosis infection. The aim of the present study was to invest...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental and therapeutic medicine 2016-09, Vol.12 (3), p.1693-1704
Hauptverfasser:	Wang, Qiang, Wen, Zhenzhen, Cao, Qian
Format:	Artikel
Sprache:	eng
Schlagworte:	Complications and side effects Dosage and administration Drug therapy Immunotherapy Infections Inflammatory bowel disease Inflammatory bowel diseases Infliximab Meta-analysis Monoclonal antibodies Quality Rheumatoid arthritis Risk factors Spondyloarthropathies spondyloarthropathy Studies Tuberculosis tuberculosis infection Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!